Halozyme Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Halozyme Therapeutics, Inc.
Teva announced the appointment of former Sandoz CEO Richard Francis as its next leader as Kare Schultz steps down.
The US Court of Appeals rejected all arguments brought by Alvogen and Natco in their appeal against an unfavorable lower court Imbruvica (ibrutinib) ruling, leaving the ANDA sponsors facing a significant wait to potential approval and launch.
Strides sees Kauliv, a biosimilar to Eli Lilly’s Forsteo, as a ‘significant’ but ‘not a massive product’ as it prepares to register it in multiple countries post a positive opinion from EMA. Meanwhile, more clarity on fund raising for Stelis is expected by March 2023 even as the regulatory timeline for a COVID-19 vaccine from Akston is extended by 2-3 months
Generic Revlimid and lanreotide propel Cipla’s US business to a high in the fiscal second quarter, with products like leuprolide depot set for debut ‘any time now’. Management signals cost edge for generic Advair as it awaits further word following a FDA establishment inspection report at its Indian site, while a Plan B is being initiated for generic Abraxane.
- Drug Delivery
- Drug Discovery Tools
- Other Names / Subsidiaries
- Antares Pharma, Inc.